GNRH AGONIST ANALOG THERAPY IN ADVANCED RECURRENT GRANULOSA-CELL TUMORS - FURTHER EVIDENCE OF A ROLE OF INHIBIN IN MONITORING RESPONSE TO TREATMENT

被引：38

作者：

KAUPPILA, A

BANGAH, M

BURGER, H

MARTIKAINEN, H

机构：

[1] Department of Obstetrics and Gynecology, University of Oulu

[2] Prince Henry's Institute of Medical Research, Melbourne

来源：

GYNECOLOGICAL ENDOCRINOLOGY | 1992年 / 6卷 / 04期

关键词：

HUMAN GRANULOSA CELL TUMOR; GONADOTROPIN RELEASING HORMONE AGONIST ANALOG THERAPY; RADIOIMMUNOASSAY; INHIBIN;

D O I：

10.3109/09513599209024990

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Five patients with advanced ovarian granulosa cell malignancies resistant to cytoxic chemotherapy were treated with monthly subcutaneous injections of long-acting gonadotropin releasing hormone (GnRH) agonist analog. One partial response and one stabilization of the disease were observed. In three patients, the tumor continued to progress. Treatment response was monitored with serum inhibin assay. Four patients had high serum inhibin concentrations at the beginning of GnRH analog treatment, while one patient had an inhibin-negative tumor. In three of four patients, serum inhibin remained relatively constant, or decreased during the first 3 months of therapy. It subsequently increased, in parallel with clinical deterioration. Further clinical trials with GnRH analogs are warranted in this malignancy in which serum inhibin appeared to be a clinically valuable tumor marker.

引用

页码：271 / 274

页数：4

共 18 条

[1]

Biskind M.S., Biskind G.S., Development of tumours in the rat ovary after transplantation into the spleen, Proc. Soc. Exp. Biol, 55, (1944)

[2]

Hofman J., Holzel F., Hackenberg R., Schulz K., EGF-related compounds from a commercial HCG-preparation as stimulatory factors for human carcinoma cell growth, J. Steroid Biochem, 28, (1987)

[3]

Simon W.E., Albrecht M., Hansel M., Dietel M., Holzel F., Cell lines derived from human ovarian carcinomas: growth stimulation by gonadotropic and steroid hormones, J. Natl. Cancer Inst, 70, (1983)

[4]

Cramer D.W., Hutchison G.B., Welch W.R., Scully R.E., Ryan K.J., Determinants of ovarian cancer risk. II. Interferences regarding pathogenesis, J. Natl. Cancer Inst, 71, (1983)

[5]

Parmar H., Philips R.H., Rustin G., Lightman S.L., Schally A.V., Therapy of advanced ovarian cancer with D-trp-6-LH-RH (de-capeptyl) microcapsules, Biomed. Pharmacother, 42, (1988)

[6]

Bruckner H.W., Motwani B.T., Treatment of advanced refractory ovarian carcinoma with a gondotropin-releasing hormone analogue, Am. J. Obstet. Gynecol, 161, (1989)

[7]

Jager W., Wildt L., Lang N., Some observations on the effect of a GnRH analog in ovarian cancer, Eur. J. Obstet. Gynecol. Reprod. Biol, 32, (1989)

[8]

Kaye S.B., Davies E., Cyclophosphamide, adriamycin and cis-platinum for the treatment of advanced granulosa cell tumor, using estradiol as a tumor marker, Gynecol. Oncol, 24, (1986)

[9]

Lappohn R.E., Burger H.G., Bouma J., Bangah M., Krans M., De Bruijn H.W.A., Inhibin as a marker for granulosa-cell tumors, N. Engl. J. Med, 321, (1989)

[10]

Martikainen H., Penttinen J., Huhtaniemi I., Kauppila A., Gonadotropin-releasing hormone agonist analog therapy effective in ovarian granulosa cell malignancy, Gynecol. Oncol, 35, (1989)

← 1 2 →